LABORATOIRES-DELBERT
Laboratoires DELBERT is Proud to Announce the Acquisition From Sanofi of TERALITHE 250 mg, Divisible Tablet and TERALITHE LP 400 mg, Prolonged-Release Tablet and Continues to Engage for Maintaining Access For Patients to MITM
Today, Laboratoires DELBERT is proud to announce the signature with Sanofi on March 31st, 2022 of the acquisition of Teralithe 250mg, divisible tablet and Teralithe LP 400mg, prolonged-release tablet (lithium carbonate) in France.
Laboratoires DELBERT (https://laboratoires-delbert.fr/ ) is a French Pharmaceutical company specialized in the « Revival of essential medications » : Marketing discontinuation, stock shortages …affect more and more essential medications especially in crisis periods with the consequence of narrowing the therapeutic arsenal of doctors that may force well-controlled patients to switch to other therapies.
With this acquisition Laboratoires DELBERT reinforces the execution of their strategy in order to ensure safe and continuous availability of Essential Medications to patients and reinforce their CNS portfolio.
“This acquisition demonstrates our ongoing commitment to invest in Major Therapeutical Interest Medications (MITM). Maintaining these medications available for patients in need is our priority,” said Marc Childs, & Thierry Hoffmann co-founders of Laboratoires DELBERT, « Laboratoires DELBERT built up over the time a portfolio of MITM that is anchored in 3 specific therapeutic areas : Antiinfectives, CNS and Oncology. »
Laboratoires DELBERT will reach over 30m€ sales by 2022 with double digit growth every year and already commercializes 14 products (out of which 13 princeps) for hospitals/specialists prescriptions.
Laboratoires DELBERT financed this acquisition thanks to very strong relationship with its financial partners who strongly believe in their values focused on patients access to MITM.
About Laboratoires DELBERT
Laboratoires DELBERT’ mission is to maintain Major Therapeutical Intererest Medication (MITM) and frequently used, available for patients.
Every year Laboratoires Delbert acquires new specialities with compromised future.
Laboratoires DELBERT focus their efforts on finding production facilities mainly across Europe.
With its collaborators and support from clinicians, galenicians, chemists Laboratoires DELBERT revive those medications and ensure their availability for clinicians and their patients in needs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220424005065/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BEHAVOX16.5.2022 15:05:13 CEST | Press release
Behavox Research on Continual Learning Featured in International Conference on Acoustics, Speech and Signal Processing (ICASSP)
MEDI-GLOBE-GROUP16.5.2022 14:23:13 CEST | Press release
Innovative AI software for the detection of pancreatic diseases: first-in-human application successful
NY-SOFINNOVA/APOLLO16.5.2022 14:02:06 CEST | Press release
Sofinnova Partners and Apollo Form Strategic Partnership in Life Sciences
KAUST16.5.2022 13:44:07 CEST | Press release
KAUST Spins-in Five Cutting-Edge International Startups and Brings New Tech to Saudi Arabia
CA-QUANTA-CLOUD-TECH16.5.2022 13:02:09 CEST | Press release
QCT Delivers on the 5G Promise with Innovative Edge Infrastructures and 5G Solutions
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom